325 Recruiting Multiple Myeloma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Multiple Myeloma Studies
Registry for Adults With Plasma Cell Disorders (PCD's)
📍 North Carolina Cancer Hospital — Chapel Hill, North Carolina
View Study & Checklist ➔A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
📍 Infirmary Health - Diagnostic & Medical Clinic (DMC) — Mobile, Alabama
View Study & Checklist ➔A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
View Study & Checklist ➔Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
📍 University of Miami — Miami, Florida
View Study & Checklist ➔Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
📍 Gundersen Lutheran — La Crosse, Wisconsin
View Study & Checklist ➔Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
📍 University of Illinois at Chicago — Chicago, Illinois
View Study & Checklist ➔Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alabama Oncology — Birmingham, Alabama
View Study & Checklist ➔Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
View Study & Checklist ➔A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
📍 University of Vermont Medical Center — Burlington, Vermont
View Study & Checklist ➔Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
📍 UCI Health - Irvine Infusion Pharmacy ACC — Irvine, California
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
View Study & Checklist ➔ATRA and Carfilzomib in Plasma Cell Myeloma Patients
📍 Houston Methodist Neal Cancer Center — Houston, Texas
View Study & Checklist ➔Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
📍 Winship Cancer Institute of Emory University — Atlanta, Georgia
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
View Study & Checklist ➔Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
📍 Vanderbilt University Medical Center — Nashville, Tennessee
View Study & Checklist ➔Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔64Cu-LLP2A for Imaging Hematologic Malignancies
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
📍 University of Washington — Seattle, Washington
View Study & Checklist ➔A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
📍 Cross Cancer Institute — Edmonton, Alberta
View Study & Checklist ➔Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
📍 Local Institution - 0131 — Los Angeles, California
View Study & Checklist ➔Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
📍 University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
View Study & Checklist ➔2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Phoenix — Phoenix, Arizona
View Study & Checklist ➔A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
📍 University of Miami — Miami, Florida
View Study & Checklist ➔